Table of Contents

Experimental Evidence

Driver mutations affecting this gene in DLBCL have been experimentally demonstrated to cause a gain of function (GOF).1

Relevance tier by entity

Entity Tier Description
DLBCL 1 High-confidence DLBCL gene
FL 2 Role of MYD88 mutations in FL requires confirmation
MZL 1 High-confidence MZL gene

Mutation incidence in large patient cohorts (GAMBL reanalysis)

DLBCL

Entity Collection N mutated Incidence 95% CI
DLBCL GAMBL without Reddy 1,089 226 0.2075 [0.1834,0.2316]
DLBCL GAMBL with Reddy 2,088 377 0.1806 [0.1641,0.1971]
DLBCL BC 231 36 0.1558 [0.1091,0.2026]
DLBCL Dana-Farber 303 57 0.1881 [0.1441,0.2321]
DLBCL NCI 470 124 0.2638 [0.224,0.3037]
DLBCL Reddy 999 151 0.1512 [0.1289,0.1734]
DLBCL DLBCL_ICGC 85 9 0.1059 [0.0405,0.1713]

FL

pathology Collection N mutated Incidence CI
FL GAMBL without Crouch 642 8 0.0125 [0.0039,0.021]
FL GAMBL with Crouch 1,189 16 0.0135 [0.0069,0.02]
FL BC 379 5 0.0132 [0.0017,0.0247]
FL Kalmbach 164 1 0.0061 [0,0.018]
FL Crouch 547 8 0.0146 [0.0046,0.0247]
FL FL_ICGC 99 2 0.0202 [0,0.0479]

Mutation pattern and selective pressure estimates

Entity Missense dN/dS Nonsense dN/dS Q value
BL 1.3373 0.0000 1
FL 9.5855 0.0000 1
DLBCL 47.3156 1.2771 0

MYD88 Hotspots

Chromosome Coordinate (hg19) ref>alt HGVSp
chr3 38182641 T>C L265P

Visualizations

Protein

View coding variants in ProteinPaint hg19 or hg38

Genome

View all variants in GenomePaint hg19 or hg38

Expression

History

%%{init: { 'logLevel': 'debug', 'theme': 'dark' } }%% timeline title Publication timing 2011-02-03 : Ngo : DLBCL 2012-04-01 : Yan : MZL

References

1.
Ngo VN, Young RM, Schmitz R, Jhavar S, Xiao W, Lim KH, Kohlhammer H, Xu W, Yang Y, Zhao H, Shaffer AL, Romesser P, Wright G, Powell J, Rosenwald A, Muller-Hermelink HK, Ott G, Gascoyne RD, Connors JM, Rimsza LM, Campo E, Jaffe ES, Delabie J, Smeland EB, Fisher RI, Braziel RM, Tubbs RR, Cook JR, Weisenburger DD, Chan WC, Staudt LM. Oncogenically active MYD88 mutations in human lymphoma. Nature. 2011 Feb 3;470(7332):115–119. PMCID: PMC5024568
2.
Yan Q, Huang Y, Watkins AJ, Kocialkowski S, Zeng N, Hamoudi RA, Isaacson PG, de Leval L, Wotherspoon A, Du MQ. BCR and TLR signaling pathways are recurrently targeted by genetic changes in splenic marginal zone lymphomas. Haematologica. 2012 Apr;97(4):595–598. PMCID: PMC3347666

Citing

If you use the information or data from this site, please cite

Krysta Coyle, Kostiantyn Dreval, Daniel Hodson and Ryan D. Morin. Audit of B-cell cancer genes. Blood Adv (2025) 9 (8): 2019–2031.

Disclaimer

The content in these pages has been populated, in part, by an automated process. Although we have scrutinized every page to ensure accuracy, errors will inevitably exist. If you find an error please report it as an issue and we will address it.

License

This work is licensed under a Creative Commons Attribution 4.0 International License.

You are free to:

Share — copy and redistribute the material in any medium or format for any purpose, even commercially.

Adapt — remix, transform, and build upon the material for any purpose, even commercially. The licensor cannot revoke these freedoms as long as you follow the license terms.